| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
1 The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University; 2 The Graduate Program in Cellular and Molecular Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland; and 3 Research Institute of Molecular Pathology, The Vienna Biocenter, Vienna, Austria
Requests for reprints: Stephen B. Baylin, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Suite 541, 1650 Orleans Street, Baltimore, MD 21231. Phone: 410-955-5806; Fax: 410-614-9884; E-mail: sbaylin{at}jhmi.edu.
Histone H3 lysine 9 (H3K9) and lysine 27 (H3K27) trimethylation are properties of stably silenced heterochromatin whereas H3K9 dimethylation (H3K9me2) is important for euchromatic gene repression. In colorectal cancer cells, all of these marks, as well as the key enzymes which establish them, surround the hMLH1 promoter when it is DNA hypermethylated and aberrantly silenced, but are absent when the gene is unmethylated and fully expressed in a euchromatic state. When the aberrantly silenced gene is DNA demethylated and reexpressed following 5-aza-2'-deoxycytidine treatment, H3K9me1 and H3K9me2 are the only silencing marks that are lost. A series of other silenced and DNA hypermethylated gene promoters behave identically even when the genes are chronically DNA demethylated and reexpressed after genetic knockout of DNA methyltransferases. Our data indicate that when transcription of DNA hypermethylated genes is activated in cancer cells, their promoters remain in an environment with certain heterochromatic characteristics. This finding has important implications for the translational goal of reactivating aberrantly silenced cancer genes as a therapeutic maneuver. (Cancer Res 2006; 66(7): 3541-9)
This article has been cited by other articles:
|
|
 |
|
  Y. Ye, M. A. McDevitt, M. Guo, W. Zhang, O. Galm, S. D. Gore, J. E. Karp, J. P. Maciejewski, J. Kowalski, H.-L. Tsai, et al. Progressive Chromatin Repression and Promoter Methylation of CTNNA1 Associated with Advanced Myeloid Malignancies Cancer Res., November 1, 2009; 69(21): 8482 - 8490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Jin, B. Yao, J.-L. Li, C. R. Fields, A. L. Delmas, C. Liu, and K. D. Robertson DNMT1 and DNMT3B Modulate Distinct Polycomb-Mediated Histone Modifications in Colon Cancer Cancer Res., September 15, 2009; 69(18): 7412 - 7421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Mohammad, Y. Cai, K. M. McGarvey, H. Easwaran, L. Van Neste, J. E. Ohm, H. M. O'Hagan, and S. B. Baylin Polycomb CBX7 Promotes Initiation of Heritable Repression of Genes Frequently Silenced with Cancer-Specific DNA Hypermethylation Cancer Res., August 1, 2009; 69(15): 6322 - 6330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. McCabe, J. C. Brandes, and P. M. Vertino Cancer DNA Methylation: Molecular Mechanisms and Clinical Implications Clin. Cancer Res., June 15, 2009; 15(12): 3927 - 3937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K J Dudley, K Revill, R N Clayton, and W E Farrell Pituitary tumours: all silent on the epigenetics front J. Mol. Endocrinol., June 1, 2009; 42(6): 461 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ellis, P. W. Atadja, and R. W. Johnstone Epigenetics in cancer: Targeting chromatin modifications Mol. Cancer Ther., June 1, 2009; 8(6): 1409 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Datta, K. Ghoshal, W. A. Denny, S. A. Gamage, D. G. Brooke, P. Phiasivongsa, S. Redkar, and S. T. Jacob A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its Degradation Cancer Res., May 15, 2009; 69(10): 4277 - 4285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Riclet, M. Chendeb, J.-L. Vonesch, D. Koczan, H.-J. Thiesen, R. Losson, and F. Cammas Disruption of the Interaction between Transcriptional Intermediary Factor 1{beta} and Heterochromatin Protein 1 Leads to a Switch from DNA Hyper- to Hypomethylation and H3K9 to H3K27 Trimethylation on the MEST Promoter Correlating with Gene Reactivation Mol. Biol. Cell, January 1, 2009; 20(1): 296 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Xu, C.-L. Wei, F. Lin, and W.-K. Sung An HMM approach to genome-wide identification of differential histone modification sites from ChIP-seq data Bioinformatics, October 15, 2008; 24(20): 2344 - 2349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Yi, H.-C. Tsai, S. C. Glockner, S. Lin, J. E. Ohm, H. Easwaran, C. D. James, J. F. Costello, G. Riggins, C. G. Eberhart, et al. Abnormal DNA Methylation of CD133 in Colorectal and Glioblastoma Tumors Cancer Res., October 1, 2008; 68(19): 8094 - 8103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhu, X. Mao, R. Hurren, A. D. Schimmer, S. Ezzat, and S. L. Asa Deoxyribonucleic Acid Methyltransferase 3B Promotes Epigenetic Silencing through Histone 3 Chromatin Modifications in Pituitary Cells J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3610 - 3617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. McGarvey, L. Van Neste, L. Cope, J. E. Ohm, J. G. Herman, W. Van Criekinge, K. E. Schuebel, and S. B. Baylin Defining a Chromatin Pattern that Characterizes DNA-Hypermethylated Genes in Colon Cancer Cells Cancer Res., July 15, 2008; 68(14): 5753 - 5759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. K. Tiwari, L. Cope, K. M. McGarvey, J. E. Ohm, and S. B. Baylin A novel 6C assay uncovers Polycomb-mediated higher order chromatin conformations Genome Res., July 1, 2008; 18(7): 1171 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Ting, H. Suzuki, L. Cope, K. E. Schuebel, B. H. Lee, M. Toyota, K. Imai, Y. Shinomura, T. Tokino, and S. B. Baylin A Requirement for DICER to Maintain Full Promoter CpG Island Hypermethylation in Human Cancer Cells Cancer Res., April 15, 2008; 68(8): 2570 - 2575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Briggs, I. M. Corcoran-Schwartz, W. Zhang, T. Harcke, W. L. Devereux, S. B. Baylin, C. G. Eberhart, and D. N. Watkins Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma Genes & Dev., March 15, 2008; 22(6): 770 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schnekenburger, G. Talaska, and A. Puga Chromium Cross-Links Histone Deacetylase 1-DNA Methyltransferase 1 Complexes to Chromatin, Inhibiting Histone-Remodeling Marks Critical for Transcriptional Activation Mol. Cell. Biol., October 15, 2007; 27(20): 7089 - 7101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hucl, J. R. Brody, E. Gallmeier, C. A. Iacobuzio-Donahue, I. K. Farrance, and S. E. Kern High Cancer-Specific Expression of Mesothelin (MSLN) Is Attributable to an Upstream Enhancer Containing a Transcription Enhancer Factor Dependent MCAT Motif Cancer Res., October 1, 2007; 67(19): 9055 - 9065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Hitchins, V. A. Lin, A. Buckle, K. Cheong, N. Halani, S. Ku, C.-T. Kwok, D. Packham, C. M. Suter, A. Meagher, et al. Epigenetic Inactivation of a Cluster of Genes Flanking MLH1 in Microsatellite-Unstable Colorectal Cancer Cancer Res., October 1, 2007; 67(19): 9107 - 9116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Rincon-Arano, M. Furlan-Magaril, and F. Recillas-Targa Protection against telomeric position effects by the chicken cHS4 beta-globin insulator PNAS, August 28, 2007; 104(35): 14044 - 14049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. V. Jacinto and M. Esteller Mutator pathways unleashed by epigenetic silencing in human cancer Mutagenesis, July 1, 2007; 22(4): 247 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. McGarvey, E. Greene, J. A. Fahrner, T. Jenuwein, and S. B. Baylin DNA Methylation and Complete Transcriptional Silencing of Cancer Genes Persist after Depletion of EZH2 Cancer Res., June 1, 2007; 67(11): 5097 - 5102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Huang, E. Greene, T. Murray Stewart, A. C. Goodwin, S. B. Baylin, P. M. Woster, and R. A. Casero Jr Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes PNAS, May 8, 2007; 104(19): 8023 - 8028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhu, K. Lee, S. L. Asa, and S. Ezzat Epigenetic Silencing through DNA and Histone Methylation of Fibroblast Growth Factor Receptor 2 in Neoplastic Pituitary Cells Am. J. Pathol., May 1, 2007; 170(5): 1618 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. De La Rosa-Velazquez, H. Rincon-Arano, L. Benitez-Bribiesca, and F. Recillas-Targa Epigenetic Regulation of the Human Retinoblastoma Tumor Suppressor Gene Promoter by CTCF Cancer Res., March 15, 2007; 67(6): 2577 - 2585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Zinn, K. Pruitt, S. Eguchi, S. B. Baylin, and J. G. Herman hTERT Is Expressed in Cancer Cell Lines Despite Promoter DNA Methylation by Preservation of Unmethylated DNA and Active Chromatin around the Transcription Start Site Cancer Res., January 1, 2007; 67(1): 194 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Egger, A. M. Aparicio, S. G. Escobar, and P. A. Jones Inhibition of Histone Deacetylation Does Not Block Resilencing of p16 after 5-Aza-2'-Deoxycytidine Treatment Cancer Res., January 1, 2007; 67(1): 346 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J J L Wong, N J Hawkins, and R L Ward Colorectal cancer: a model for epigenetic tumorigenesis Gut, January 1, 2007; 56(1): 140 - 148. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Ting, K. M. McGarvey, and S. B. Baylin The cancer epigenome--components and functional correlates Genes & Dev., December 1, 2006; 20(23): 3215 - 3231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chen, Y. Yan, T. L. Davidson, Y. Shinkai, and M. Costa Hypoxic Stress Induces Dimethylated Histone H3 Lysine 9 through Histone Methyltransferase G9a in Mammalian Cells. Cancer Res., September 15, 2006; 66(18): 9009 - 9016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Foltz, G.-Y. Ryu, J.-G. Yoon, T. Nelson, J. Fahey, A. Frakes, H. Lee, L. Field, K. Zander, Z. Sibenaller, et al. Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma. Cancer Res., July 1, 2006; 66(13): 6665 - 6674. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
